Latest Observability News

LTR Pharma has successfully completed the extractables study for its intranasal erectile dysfunction spray SPONTAN, confirming safety compliance and initiating the next phase of leachables testing to support FDA approval.

Zinc of Ireland NL’s maiden drilling at Mt Clere has intersected sulphide zones consistent with SEDEX-style mineralisation, highlighting promising base metal potential at the Robin 21 anomaly. Two diamond drill holes totaling over 1,100 metres reveal encouraging geological signatures ahead of detailed assays.

GTN Limited is set to seek shareholder approval for a substantial $44 million capital return, aiming to reward investors without compromising its dividend policy.

Epsilon Healthcare and its subsidiaries have officially exited voluntary administration and Deeds of Company Arrangement, marking a pivotal recovery milestone supported by significant personal commitments from the new board. The company now shifts focus to strategic growth and rebuilding trust.

Whitebark Energy has finalized a preliminary well design and rig market assessment for drilling the massive Rickerscote prospect in 2026, estimating costs at AU$7.7 million. The move positions the company at the forefront of Australia's emerging hydrogen, helium, and hydrocarbon sectors.

The Takeovers Panel has declined to review its earlier decision on Keybridge Capital's board reshuffle, dismissing Yowie Group's challenge and signaling a firm stance on takeover conduct.

Locate Technologies Limited has responded to an ASX inquiry about unusual trading activity, confirming no undisclosed information and compliance with listing rules. The company points to recent capital raising announcements as context for the share price movement.

Westpac Banking Corporation announces a fully franked distribution of AUD 1.2463 per Capital Note 7 for Q3 2025, reflecting a 4.9447% annualised rate based on the 3-month BBSW plus margin.

Westpac Banking Corporation announces a fully franked distribution of AUD 1.2110 per Westpac Capital Notes 5 for the quarter ending September 2025, reflecting a 4.8047% annualised rate based on prevailing market benchmarks.

The Takeovers Panel has declined to declare unacceptable circumstances in a dispute involving Mayfield Childcare Limited shareholders but has referred potential breaches of takeover laws to ASIC for further investigation.

Neuren Pharmaceuticals has been granted a US patent for NNZ-2591 to treat Pitt Hopkins syndrome, bolstered by promising Phase 2 clinical trial results and FDA orphan drug status.

New Frontier Minerals has finalized key drill targets for Heavy Rare Earth Elements, Niobium, and Uranium at its Harts Range Project, supported by a $59,000 Northern Territory government grant and progressing towards a maiden drilling campaign.